Synthetic Cell Produces Anti-Cancer Drugs Within a Tumor
February 12, 2018
Technion researchers have successfully treated a cancerous tumor using a “nano-factory” — a synthetic cell that produces anti-cancer proteins within the tumor tissue. The research, which was published in Advanced Healthcare Materials, combines synthetic biology, to artificially produce proteins, and targeted drug delivery, to direct the synthetic cell to abnormal tissues.
The synthetic cells are artificial systems with capacities similar to, and, at times, superior to those of natural cells. Just as human cells can generate a variety of biological molecules, the synthetic cell can produce a wide range of proteins. Such systems bear vast potential in the tissue engineering discipline, in production of artificial organs and in studying the origins of life.
Design of artificial cells is a considerably complex engineering challenge being pursued by many research groups across the globe. The present research, in which an artificial cell serves as a nanofactory for generating proteins within abnormal tissue, was led by the doctoral student Nitzan Krinsky and Assistant Professor Avi Schroeder, at the Wolfson Faculty of Chemical Engineering at the Technion.
The researchers integrated molecular machines within lipid-based particles resembling the natural membrane of biological cells. They engineered the particles such that when they “sense” the biological tissue, they are activated and produce therapeutic proteins, dictated by an integrated synthetic DNA template. The particles recruit the energy sources and building blocks necessary for their continued activity, from the external microenvironment (e.g., the tumor tissue).
After experiments in cell cultures in the lab, the novel technology was also tested in mice. When the engineered particles reached the tumor, they produced a protein that eradicated the cancer cells. The particles and their activity were monitored using a green fluorescent protein (GFP), generated by the particles. This protein can be viewed in real-time, using a fluorescence microscope.
“By coding the integrated DNA template, the particles we developed can produce a variety of protein medicines,” said Professor Schroeder. “They are modular, meaning they allow for activation of protein production in accordance with the environmental conditions. Therefore, the artificial cells we’ve developed at the Technion may take an important part in the personalized medicine trend — adjustment of treatment to the genetic and medical profile of a specific patient.”
The research was performed in collaboration with Professor Itai Benhar from Tel Aviv University and Dr. Dov Hershkovitz from the Sourasky Medical Center. The research was supported by the Technion Integrated Cancer Center (TICC), the Russell Berrie Nanotechnology Institute, the Lorry I. Lokey Interdisciplinary Center for Life Sciences & Engineering, the Pre-linical Research Authority staff and the Biomedical Core Facility at the Rappaport Faculty of Medicine.
For more than a century, the Technion – Israel Institute of Technology has pioneered in science and technology education and delivered world-changing impact. Proudly a global university, the Technion has long leveraged boundary-crossing collaborations to advance breakthrough research and technologies. Now with a presence in three countries, the Technion will prepare the next generation of global innovators. Technion people, ideas and inventions make immeasurable contributions to the world, innovating in fields from cancer research and sustainable energy to quantum computing and computer science to do good around the world.
The American Technion Society supports visionary education and world-changing impact through the Technion – Israel Institute of Technology. Based in New York City, we represent thousands of US donors, alumni and stakeholders who invest in the Technion’s growth and innovation to advance critical research and technologies that serve the State of Israel and the global good. Over more than 75 years, our nationwide supporter network has funded new Technion scholarships, research, labs, and facilities that have helped deliver world-changing contributions and extend Technion education to campuses in three countries.